BerGenBio ASA (BRRGF) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BerGenBio ASA has appointed Olav Hellebø as its new CEO, bringing extensive experience from the pharmaceutical and biotechnology industries to the company. Hellebø’s leadership is expected to drive the development of BerGenBio’s lead candidate, bemcentinib, aimed at treating STK11 mutated non-small cell lung cancer. Investors and stakeholders may find this leadership change promising for the company’s strategic growth and clinical advancement.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
